Download presentation
Presentation is loading. Please wait.
1
What's New in Dyslipidemia?
3
Overview
4
LDL-C vs CV Events Secondary Prevention Studies
5
High- vs Low-Dose Statin
6
The Statin Hypothesis Low vs High Dose
7
LDL-C Level vs Statin Intensity
8
Lipoprotein Abnormalities in T2D
9
Lipoprotein Abnormalities in T2D (cont)
11
T2D as a CVD Risk Equivalent
12
The Role of Statins 2013 ACC/AHA Guidelines
13
2013 ACC/AHA Cholesterol Guidelines 4 Statin Benefit Groups Identified
14
2014 NLA Criteria for Treatment Initiation According to Risk
15
2016 Consensus Statement From ACC/AHA and NLA
16
Intensity of Statin Treatment
17
Role of Metabolic Syndrome
18
Statin Nonadherence and Intolerance
19
Statin Discontinuation After ACS Clinical Consequences
20
Statin Discontinuation in RCTs
21
Statin Adherence in Registry Databases
22
Keep in Mind…
23
Issues With Recommendations Based on Statin Intensity
24
Approaches to Lipid Treatment in T2D 2016 AACE/ACE Algorithm
26
Role of PCSK9 Inhibitors
27
ODYSSEY LONG TERM Alirocumab 150 mg vs Placebo 2:1
28
ODYSSEY LONG TERM (cont)
29
OSLER Evolocumab + Standard Therapy vs Standard Therapy Alone 2:1
31
ODYSSEY LONG TERM AEs by Achieved LDL-C
34
GAUSS-2 and ODYSSEY ALTERNATIVE PCSK9 Inhibitors Well Tolerated by Statin-intolerant Patients
35
Incorporating PCSK9 Inhibitors Into Endocrinology Practice
36
Abbreviations
37
Abbreviations (cont)
38
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.